• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Citigroup initiated coverage on Kiniksa Pharmaceuticals with a new price target

    3/13/25 7:43:42 AM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KNSA alert in real time by email
    Citigroup initiated coverage of Kiniksa Pharmaceuticals with a rating of Buy and set a new price target of $40.00
    Get the next $KNSA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KNSA

    DatePrice TargetRatingAnalyst
    9/29/2025$60.00Buy
    TD Cowen
    3/13/2025$40.00Buy
    Citigroup
    9/13/2024$40.00Buy
    Jefferies
    5/3/2024$34.00Overweight
    Wells Fargo
    12/29/2021$37.00 → $34.00Buy
    B of A Securities
    More analyst ratings

    $KNSA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHAIRMAN & CEO Patel Sanj K exercised 257,969 units of Class A Ordinary Share at a strike of $3.80 and sold $10,023,532 worth of Class A Ordinary Share (257,969 units at $38.86) (SEC Form 4)

    4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)

    10/22/25 5:09:09 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF ACCOUNTING OFFICER Megna Michael R exercised 39,435 units of Class A Ordinary Share at a strike of $11.59 and sold $1,962,781 worth of Class A Ordinary Share (50,490 units at $38.87), decreasing direct ownership by 29% to 27,046 units (SEC Form 4)

    4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)

    10/22/25 5:06:50 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF OPERATING OFFICER Tessari Eben exercised 6,500 units of Class A Ordinary Share at a strike of $8.83 and sold $465,843 worth of Class A Ordinary Share (12,368 units at $37.67), decreasing direct ownership by 17% to 28,684 units (SEC Form 4)

    4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)

    10/16/25 4:35:05 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KNSA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis

    LONDON, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to KPL-387 for the treatment of pericarditis, which includes recurrent pericarditis. KPL-387 is an independently developed monoclonal antibody that binds human interleukin-1 receptor 1 (IL-1R1), inhibiting the signaling activity of the cytokines interleukin-1α (IL-1α) and interleukin-1β (IL-1β). "We are pleased to announce that yesterday t

    10/17/25 8:00:00 AM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

    LONDON, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) today announced that management will participate in fireside chats at the following investor conferences in September: Citi 2025 Biopharma Back to School Summit on Wednesday, September 3 at 9:00 a.m. Eastern Time2025 Wells Fargo Healthcare Conference on Thursday, September 4 at 9:30 a.m. Eastern Time A live webcast of Kiniksa's presentations will be accessible through the Investors & Media section of the company's website at www.kiniksa.com. A replay of the events will also be available on Kiniksa's website within approximately 48 hours after the event. About KiniksaKiniksa is a biop

    8/28/25 4:01:00 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution

    – ARCALYST® (rilonacept) Q2 2025 net product revenue of $156.8 million, representing 52% year-over-year growth –– ARCALYST 2025 expected net product revenue increased to $625 - $640 million –– KPL-387 Phase 2/3 clinical trial in recurrent pericarditis initiated; Phase 2 data expected in 2H 2026 –– Cash balance increased by $39.4 million in Q2 2025 to $307.8 million –– Conference call and webcast scheduled for 8:30 am ET today – LONDON, July 29, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today

    7/29/25 7:30:00 AM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KNSA
    SEC Filings

    View All

    SEC Form 144 filed by Kiniksa Pharmaceuticals International plc

    144 - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)

    10/20/25 5:49:57 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Kiniksa Pharmaceuticals International plc

    144 - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)

    10/20/25 5:48:40 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Kiniksa Pharmaceuticals International plc

    144 - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)

    9/3/25 4:56:49 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KNSA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen initiated coverage on Kiniksa Pharmaceuticals with a new price target

    TD Cowen initiated coverage of Kiniksa Pharmaceuticals with a rating of Buy and set a new price target of $60.00

    9/29/25 9:58:02 AM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup initiated coverage on Kiniksa Pharmaceuticals with a new price target

    Citigroup initiated coverage of Kiniksa Pharmaceuticals with a rating of Buy and set a new price target of $40.00

    3/13/25 7:43:42 AM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on Kiniksa Pharmaceuticals with a new price target

    Jefferies initiated coverage of Kiniksa Pharmaceuticals with a rating of Buy and set a new price target of $40.00

    9/13/24 7:34:05 AM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KNSA
    Financials

    Live finance-specific insights

    View All

    Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution

    – ARCALYST® (rilonacept) Q2 2025 net product revenue of $156.8 million, representing 52% year-over-year growth –– ARCALYST 2025 expected net product revenue increased to $625 - $640 million –– KPL-387 Phase 2/3 clinical trial in recurrent pericarditis initiated; Phase 2 data expected in 2H 2026 –– Cash balance increased by $39.4 million in Q2 2025 to $307.8 million –– Conference call and webcast scheduled for 8:30 am ET today – LONDON, July 29, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today

    7/29/25 7:30:00 AM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kiniksa Pharmaceuticals to Report Second Quarter 2025 Financial Results on July 29, 2025

    LONDON, July 24, 2025 (GLOBE NEWSWIRE) --  Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 29, 2025 at 8:30 a.m. Eastern Time to report its second quarter 2025 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company's website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and regis

    7/24/25 4:01:00 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution

    – ARCALYST® (rilonacept) Q1 2025 net product revenue of $137.8 million, representing 75% year-over-year growth –– ARCALYST 2025 expected net product revenue increased to $590 - $605 million –– KPL-387 Phase 2/3 clinical trial in recurrent pericarditis on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 –– Current operating plan expected to remain cash flow positive on an annual basis –– Conference call and webcast scheduled for 8:30 am ET today – LONDON, April 29, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, w

    4/29/25 7:30:00 AM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KNSA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Kiniksa Pharmaceuticals International plc

    SC 13G/A - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)

    11/14/24 4:32:31 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Kiniksa Pharmaceuticals International plc

    SC 13G/A - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)

    11/14/24 4:15:22 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Kiniksa Pharmaceuticals International plc

    SC 13G/A - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)

    11/13/24 4:30:25 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care